revumenib Publication is a Syndax Pharmaceuticals Inc program in R/R NUP98-rearranged acute leukemia. Its next catalyst is a Readout in Q4 2026.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: R/R NUP98-rearranged acute leukemia. Sponsor: Syndax Pharmaceuticals Inc (SNDX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for revumenib Publication is a Readout in Q4 2026.
No FDA decision for revumenib Publication is in our archive yet.
In our records revumenib Publication is under review or in development for R/R NUP98-rearranged acute leukemia.
Syndax Pharmaceuticals Inc (SNDX).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.